Novartis
NEWS
With ASCO set to kick off on Friday, companies prepare to share data from multiple cancer treatment pipeline programs.
The approval of Piqray combined with fulvestrant is the first FDA-approved treatment for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer.
The price of the one-and-done gene therapy treatment is about half of what was initially projected by Novartis.
Investors and analysts get a close-up look at the Swiss pharma giant’s pipeline and growth strategies.
Verily announced a strategic collaboration deal with Novartis, Otsuka, Pfizer, Sanofi and six major health systems.
Patients were randomized 1:1 to receive Nerlynx and Xeloda or Tykerb and Xeloda. Co-primary endpoints were progression-free survival and overall survival.
The two generic drugmakers, along with many others, have been accused of conspiring to inflate the price of more than 100 generic drugs.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
Today has been marked by a wide range of life science and biopharma stories. Here’s a broader look at some of the top stories.
JOBS
IN THE PRESS